Shares of Presbia PLC (NASDAQ:LENS) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Brokers have set a 12 month consensus target price of $8.50 for the company and are anticipating that the company will post ($0.11) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Presbia an industry rank of 121 out of 255 based on the ratings given to its competitors.
A number of brokerages have recently issued reports on LENS. ValuEngine raised Presbia from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. HC Wainwright set a $6.00 price target on Presbia and gave the stock a “buy” rating in a research note on Tuesday, May 29th. Finally, Zacks Investment Research lowered Presbia from a “buy” rating to a “hold” rating in a research note on Friday, June 15th.
LENS traded up $0.01 during trading on Tuesday, hitting $2.13. The company’s stock had a trading volume of 1,346 shares, compared to its average volume of 10,105. Presbia has a twelve month low of $1.79 and a twelve month high of $7.14.
Presbia (NASDAQ:LENS) last issued its quarterly earnings data on Friday, May 11th. The medical instruments supplier reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.09. research analysts anticipate that Presbia will post -0.45 earnings per share for the current year.
Presbia Company Profile
Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in South Korea, Australia, New Zealand, Italy, the Netherlands, Ireland, Canada, and Germany.
Further Reading: Penny Stocks
Get a free copy of the Zacks research report on Presbia (LENS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Presbia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia and related companies with MarketBeat.com's FREE daily email newsletter.